Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest close session, Gilead Sciences (GILD) was up +1.19% at $113.59. This change outpaced the S&P 500's 0.48% gain on the day. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.94%. The HIV and hepatitis C drugmaker's shares have seen a decrease of 5.45% over the last month, not keeping up with the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46%.Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 6.44% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 billion, showing a 1.63% drop compared to the year-ago quarter. GILD's full-year Zacks Consensus Estimates are calling for earnings of $8.1 per share and revenue of $28.75 billion. These results would represent year-over-year changes of +75.32% and 0%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now. Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 13.86. For comparison, its industry has an average Forward P/E of 20.03, which means Gilead Sciences is trading at a discount to the group. We can also see that GILD currently has a PEG ratio of 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.64. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow GILD in the coming trading sessions, be sure to utilize Zacks.com. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks